Amarin, FDA Off-Label Promotion Suit Stayed Until Feb.
By Dani Kass ( December 17, 2015, 1:03 PM EST) -- A New York federal judge on Thursday halted a suit between Amarin Pharma Inc. and the U.S. Food and Drug Administration — in which the court had previously ruled Amarin can make certain truthful statements about off-label uses of its omega-3 drug Vascepa — while the two chisel out a settlement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.